Tina Felfeli1, Verena R Juncal2, Roxane J Hillier3, Michael Y K Mak4, David T Wong2, Alan R Berger2, Radha P Kohly5, Peter J Kertes5, Kenneth T Eng5, Shelley R Boyd2, Filiberto Altomare2, Louis R Giavedoni2, Rajeev H Muni6. 1. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada. 2. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada; Department of Ophthalmology, Unity Health Toronto, St. Michael's Hospital, Toronto, Ontario, Canada. 3. Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle University, Newcastle, United Kingdom; Institute of Neuroscience, Newcastle University, Newcastle, United Kingdom. 4. Division of Ophthalmology, Department of Surgery, University of Calgary, Calgary, Alberta, Canada. 5. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada; The John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 6. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada; Department of Ophthalmology, Unity Health Toronto, St. Michael's Hospital, Toronto, Ontario, Canada. Electronic address: rajeev.muni@gmail.com.
Abstract
PURPOSE: To determine the association of aqueous humor cytokine concentrations with long-term treatment response to anti-vascular endothelial growth factor (VEGF) agents in diabetic macular edema (DME). DESIGN: Retrospective case series. METHODS: Pooled data of aqueous humor cytokine concentrations collected at baseline and 2-month follow-up (2 injections) for treatment-naïve eyes with center-involving DME previously enrolled in a prospective study were reviewed. Subjects receiving intravitreal anti-VEGF injections outside of study protocol as per standard of care were classified into Responders versus Nonresponders based on qualitative assessment of optical coherence tomography for persistence of DME at longitudinal follow-up visits. RESULTS: Of the 41 eyes, 85% were classified as Responders with a significant decline in baseline central subfield thickness and macular volume (P values < .001), and 15% were identified as Nonresponders to anti-VEGF therapy over 51.4 ± 18.7 months of follow-up. No significant difference in baseline aqueous humor VEGF concentration was noted, while at the 2-month follow-up the Nonresponder group had a significantly higher VEGF concentration compared with the Responder group (451.5 ± 690.9 pg/mL vs 113.7 ± 211.4 pg/mL; P = .02). The Responder group also demonstrated a significant decline from baseline to 2-month follow-up in concentration of intercellular adhesion molecule-1 (P < .001), interleukin-10 (P = .041), monocyte chemotactic protein-1 (P = .046), placental growth factor (P = .027), and transforming growth factor-β2 (P = .017). CONCLUSIONS: Aqueous humor cytokine concentrations serve as an early biomarker for long-term response to anti-VEGF therapy and may enable more effective treatment regimens that improve anatomical outcomes in eyes with DME.
PURPOSE: To determine the association of aqueous humor cytokine concentrations with long-term treatment response to anti-vascular endothelial growth factor (VEGF) agents in diabetic macular edema (DME). DESIGN: Retrospective case series. METHODS: Pooled data of aqueous humor cytokine concentrations collected at baseline and 2-month follow-up (2 injections) for treatment-naïve eyes with center-involving DME previously enrolled in a prospective study were reviewed. Subjects receiving intravitreal anti-VEGF injections outside of study protocol as per standard of care were classified into Responders versus Nonresponders based on qualitative assessment of optical coherence tomography for persistence of DME at longitudinal follow-up visits. RESULTS: Of the 41 eyes, 85% were classified as Responders with a significant decline in baseline central subfield thickness and macular volume (P values < .001), and 15% were identified as Nonresponders to anti-VEGF therapy over 51.4 ± 18.7 months of follow-up. No significant difference in baseline aqueous humor VEGF concentration was noted, while at the 2-month follow-up the Nonresponder group had a significantly higher VEGF concentration compared with the Responder group (451.5 ± 690.9 pg/mL vs 113.7 ± 211.4 pg/mL; P = .02). The Responder group also demonstrated a significant decline from baseline to 2-month follow-up in concentration of intercellular adhesion molecule-1 (P < .001), interleukin-10 (P = .041), monocyte chemotactic protein-1 (P = .046), placental growth factor (P = .027), and transforming growth factor-β2 (P = .017). CONCLUSIONS: Aqueous humor cytokine concentrations serve as an early biomarker for long-term response to anti-VEGF therapy and may enable more effective treatment regimens that improve anatomical outcomes in eyes with DME.
Authors: Philipp K Roberts; Wolf-Dieter Vogl; Bianca S Gerendas; Adam R Glassman; Hrvoje Bogunovic; Lee M Jampol; Ursula M Schmidt-Erfurth Journal: JAMA Ophthalmol Date: 2020-09-01 Impact factor: 7.389
Authors: Beatriz G Gálvez; Clara Martinez-Perez; Cesar Villa-Collar; Cristina Alvarez-Peregrina; Miguel Ángel Sánchez-Tena Journal: J Clin Med Date: 2022-01-27 Impact factor: 4.241
Authors: Sudeshna Sil Kar; Joseph Abraham; Charles C Wykoff; Duriye Damla Sevgi; Leina Lunasco; David M Brown; Sunil K Srivastava; Anant Madabhushi; Justis P Ehlers Journal: Ophthalmol Sci Date: 2022-02-04
Authors: Giuseppina Emanuela Grieco; Guido Sebastiani; Chiara Maria Eandi; Giovanni Neri; Laura Nigi; Noemi Brusco; Romina D'Aurizio; Matteo Posarelli; Tommaso Bacci; Elena De Benedetto; Mario Fruschelli; Maurizio Orlandini; Federico Galvagni; Francesco Dotta; Gian Marco Tosi Journal: Int J Mol Sci Date: 2020-10-03 Impact factor: 5.923